Filing Details
- Accession Number:
- 0000880771-17-000085
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-05-23 16:13:33
- Reporting Period:
- 2017-05-22
- Filing Date:
- 2017-05-23
- Accepted Time:
- 2017-05-23 16:13:33
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
880771 | Sciclone Pharmaceuticals Inc | SCLN | Pharmaceutical Preparations (2834) | 943116852 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1363213 | Friedhelm Blobel | 950 Tower Lane, Suite 900 Foster City CA 94404 | President & Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2017-05-22 | 18,536 | $3.55 | 111,062 | No | 4 | M | Direct | |
Common Stock | Disposition | 2017-05-22 | 18,536 | $9.44 | 92,526 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2017-05-22 | 18,536 | $0.00 | 18,536 | $3.55 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
169,074 | 2020-03-05 | No | 4 | M | Direct |
Footnotes
- The reported sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2016.
- Granted under the Issuer's 2005 Equity Incentive Plan.
- 25% of each shares vest one year from the date of grant, of March 5, 2010, and 2.0833% vests each month thereafter, provided that Reporting Person continues to be employed by the Issuer.